HCM
PGNX

Hollencrest Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Hollencrest Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-50,000
Closed -$211K – 420
2016
Q2 		$211K Hold
50,000
– – 0.03% 345
2016
Q1 		$218K Sell
50,000
-28
-0.1% -$125 0.04% 317
2015
Q4 		$307K Buy
50,028
+28
+0.1% +$184 0.05% 264
2015
Q3 		$286K Hold
50,000
– – 0.05% 254
2015
Q2 		$373K Hold
50,000
– – 0.05% 228
2015
Q1 		$299K Buy
+50,000
New +$315K 0.04% 274

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Hollencrest Capital Management's PGNX Position: Q3 2016 in Review

Hollencrest Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2016, closing a stake of 50,000 shares — an estimated $211K sold.

Hollencrest Capital Management first reported a position in PGNX in Q1 2015 and held it in 6 quarters. The position peaked at $373K in Q2 2015. 115 funds tracked by Wall St. Rank hold PGNX as of Q3 2016.

  • Hollencrest Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Hollencrest Capital Management sold 50,000 Progenics Pharmaceuticals Inc shares in Q3 2016, an estimated $211K.
  • Hollencrest Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 6 quarters.
  • Hollencrest Capital Management's Progenics Pharmaceuticals Inc position peaked at $373K in Q2 2015.
  • 115 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2016.

Based on Hollencrest Capital Management's 13F filing for Q3 2016, filed 12 Oct 2016.